title: Reveromycin A inhibits antigen receptor-mediated antigen presentation by B lymphoma cells via its effect on intracellular trafficking of the antigen.
abstract: Reveromycin A (Rev.A) is an inhibitor of epidermal growth factor-dependent cell growth that is produced from the culture broth of an actinomycete strain. Rev.A was assessed for its ability to regulate antigen (Ag) presentation by A20-HL B lymphoma cells bearing trinitrophenyl (TNP)-specific surface IgM (sIgM) to cloned T cells specific for OVA(323-339)/I-Ad. Rev.A-treatment inhibited the presentation of Ag internalized via sIgM, but not of Ag via fluid-phase pinocytosis. Rev.A-treatment decreased protein synthesis, but a similar decrease in protein synthesis by cycloheximide induced much less inhibition of sIgM-mediated Ag presentation. Rev.A-treatment decreased the rate of re-expression of sIgM in A20-HL cells, the amount of Ag internalized via sIgM during 3 hours of incubation, and the generation of antigenic peptides from TNP-OVA internalized via sIgM. Rev.A-treatment was suggested to affect intracellular trafficking from early endosomes into late endocytic compartments of Ag internalized via sIgM. Rev.A might provide a useful tool for studying intracellular transport of Ag, especially Ag internalized via sIgM.
authors.affiliation: Department of Immunology, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan.
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Fumio
authors.initials: F
authors.lastname: Ishikawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Osada
authors.forename: Shinobu
authors.initials: S
authors.lastname: Imajoh-Ohmi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Uchida
authors.forename: Terutaka
authors.initials: T
authors.lastname: Kakiuchi
mesh_terms: D005434:Flow Cytometry; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology; D011714:Pyrans / Q000627:therapeutic use*; D011947:Receptors, Antigen, B-Cell / Q000187:drug effects* / Q000276:immunology; D013141:Spiro Compounds / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
chemical_list: D011714:Pyrans; D011947:Receptors, Antigen, B-Cell; D013141:Spiro Compounds; C068098:reveromycin A